创伤后严重出血的院前冻干血浆输注:一项先导性随机对照试验
该先导性随机对照试验在澳大利亚航空医疗院前环境中,将直升机紧急医疗服务(HEMS)急救人员接诊的创伤后疑似严重出血且接受院前红细胞输注的患者随机分为接受2单位冻干血浆(Lyoplas N-w)组或标准治疗(不输血浆)组。主要终点为符合条件患者入组并接受干预的比例,结果显示25例符合条件患者中20例(80%)入组,19例(76%)接受了分配干预。次要终点显示冻干血浆组24小时死亡率(RR 0.24,95% CI 0.03-1.73)和出院死亡率(RR 0.73,95% CI 0.24-2.27)可能更低,但置信区间宽。未报告与试验干预相关的严重不良事件。作者认为院前给予冻干血浆是可行的,鉴于HEMS接诊通常伴随较长的院前时间,该干预可能有临床获益,并有必要开展确定性试验。
要点
- 在澳大利亚航空医疗院前环境中,创伤后疑似严重出血且接受院前红细胞输注的患者中,25例符合条件者20例(80%)入组,19例(76%)接受了冻干血浆或标准治疗干预。
- 从随机化到医院到达的中位时间为92.5分钟(IQR 68-101.5分钟)。
- 冻干血浆组24小时死亡率可能更低(RR 0.24,95% CI 0.03-1.73),出院死亡率也可能更低(RR 0.73,95% CI 0.24-2.27),但置信区间宽。
- 未报告与试验干预相关的严重不良事件。
- 作者认为院前给予冻干血浆是可行的,鉴于HEMS接诊通常伴随较长的院前时间,该干预可能有临床获益,并有必要开展确定性试验。
适用人群与场景
- 由直升机紧急医疗服务(HEMS)急救人员接诊的、创伤后疑似严重出血且接受院前红细胞输注的患者。
处置流程与药物剂量
- 冻干血浆组:接受2单位冻干血浆(Lyoplas N-w)。
- 标准治疗组:不接受血浆。
研究设计与关键结果
- 研究类型:先导性随机对照试验;研究时间:2022年6月1日至2022年10月31日;地点:澳大利亚航空医疗院前环境。
- 主要终点:符合条件患者25例,入组20例(80%),接受分配干预19例(76%)。
- 从随机化到医院到达的中位时间为92.5分钟(IQR 68-101.5分钟)。
- 24小时死亡率:冻干血浆组较标准治疗组可能更低(RR 0.24,95% CI 0.03-1.73)。
- 出院死亡率:冻干血浆组较标准治疗组可能更低(RR 0.73,95% CI 0.24-2.27)。
- 不良事件:未报告与试验干预相关的严重不良事件。
证据类型、等级与局限
- 证据类型:先导性随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在澳大利亚航空医疗院前环境中,对创伤后疑似严重出血且接受院前红细胞输注的患者给予冻干血浆是可行的。
- 作者认为,鉴于HEMS接诊通常伴随较长的院前时间,该干预可能有临床获益,并有必要开展确定性试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Transfusion of a high ratio of plasma to packed red blood cells (PRBCs), to treat or prevent acute traumatic coagulopathy, has been associated with survival after major trauma. However, the effect of prehospital plasma on patient outcomes has been inconsistent. The aim of this pilot trial was to assess the feasibility of transfusing freeze-dried plasma with red blood cells (RBCs) using a randomized controlled design in an Australian aeromedical prehospital setting.
METHODS: Patients attended by helicopter emergency medical service (HEMS) paramedics with suspected critical bleeding after trauma managed with prehospital RBCs were randomized to receive 2 units of freeze-dried plasma (Lyoplas N-w) or standard care (no plasma). The primary outcome was the proportion of eligible patients enrolled and provided the intervention. Secondary outcomes included preliminary data on effectiveness, including mortality censored at 24 h and at hospital discharge, and adverse events.
RESULTS: During the study period of June 1 to October 31, 2022, there were 25 eligible patients, of whom 20 (80%) were enrolled in the trial and 19 (76%) received the allocated intervention. Median time from randomization to hospital arrival was 92.5 min (IQR 68-101.5 min). Mortality may have been lower in the freeze-dried plasma group at 24 h (RR 0.24, 95% CI 0.03-1.73) and at hospital discharge (RR 0.73, 95% CI 0.24-2.27). No serious adverse events related to the trial interventions were reported.
CONCLUSIONS: This first reported experience of freeze-dried plasma use in Australia suggests prehospital administration is feasible. Given longer prehospital times typically associated with HEMS attendance, there is potential clinical benefit from this intervention and rationale for a definitive trial.
参考来源
- Mitra B, Meadley B, Bernard S, et al. Pre-hospital freeze-dried plasma for critical bleeding after trauma: A pilot randomized controlled trial. Acad Emerg Med. 2023. PMID: 37103482. doi:10.1111/acem.14745
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。